Therefore, we underscore the importance of providers routinely pursuing genetic testing for the BCR/ABL gene in both PB and BM as part of the workup for patients with isolated thrombocytosis to avoid misdiagnosis or delayed diagnosis of CML in this patient population. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.